Diagnostic procedures and rationale for specific therapies in chronic kidney disease-mineral and bone disorder

Contributions to Nephrology

Volumn 161, Issue , 2008, Pages 222-233

  Bover, J ^a,c   Canal, C ^a   Marco, H ^a   Fernandez Llama, P ^a   Bosch, R ^b   Ballarin J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MINERAL;

BONE DENSITY; BONE DISEASE; CALCINOSIS; CHRONIC DISEASE; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DISEASE; METABOLISM; PRIMARY HYPERPARATHYROIDISM; RENAL OSTEODYSTROPHY; REVIEW; VASCULAR DISEASE;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES; CALCINOSIS; CHRONIC DISEASE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPERPHOSPHATEMIA; KIDNEY DISEASES; MINERALS; RENAL OSTEODYSTROPHY; VASCULAR DISEASES;

EID: 48049110547     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000130690     Document Type: Conference Paper

References (29)

1. Bover J, Canal C, Pérez SG, Bosch RJ, Ballarín JA: Slowing the progression of vascular calcification in chronic kidney disease patients. Eur Renal Dis 2007;1:18-23.
2. Gracia S, Montañés R, Bover J, Cases A, Deulofeu R, Martín de Francisco AL, Orte LM, on behalf of the Spanish Society of Nephrology: Recommendations for the use of equations to estimate glomerular filtration rate in adults. Nefrologia 2006;26:658-665.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
4. Llach F, Bover J: Renal osteodystrophies; in Brenner BM (ed): The Kidney. Philadelphia, Saunders, 2000, pp 2103-2186.
5. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from KDIGO. Kidney Int 2006;69:1945-1953.
6. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl 3):S1-S201.
7. Torregrosa V, Cannata J, Bover J, et al: Recommendations of the Spanish Society of Nephrology for the treatment of mineral and bone metabolism disorders in patients with chronic kidney disease. Nefrologia 2008 (in press).
8. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH, Sevelamer Study Group: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008;19:405-412.
9. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
10. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-1013.
11. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Gonçalves M, Negrao AP: A simple vascular calcification score predicts cardiovascular risk in hemodialysis patients. Nephrol Dial Transplant 2004;19:1480-1488.
12. Bellasi A, Ferramosca E, Muntner P, Ratti C, Wildman RP, Block GA, Raggi P: Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int 2006;70:1623-1628.
13. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
14. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-441.
15. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
16. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-1824.
17. Guérin AP, Pannier B, Marchais SJ, London GM: Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Curr Opin Nephrol Hypertens 2006;15:105-110.
18. Goldsmith DR, Scott LJ, Cvetković RS, Plosker GL: Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 2008;68:85-104.
19. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003;64:1653-1661.
20. Mendoza FJ, Lopez I, Montes de Oca A, Perez J, Rodriguez M, Aguilera-Tejero E: Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int 2008;73:407-414.
21. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-1137.
22. Andress DL: Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006;69:33-43.
23. Marco MP, Craver L, Betriu A, Fibla J, Fernández E: Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients. Am J Kidney Dis 2001;38:965-974.
24. Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-866.
25. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456.
26. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ: Achieving NKFK/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-771.
27. Schaefer RM, Bover J, Dellanna F, Sanz D, Asensio C, Sánchez González MC, Gross P, Zani V, Carter D, Jehle PM. Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR study. Clin Nephrol 2008 (submitted).
28. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-1800.
29. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M: The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008;73:300-307.